Get the Stockscreener App
3.42
2.01%
-0.07
After Hours:
3.45
0.03
+0.88%
Briacell Therapeutics Corp stock is traded at $3.42, with a volume of 187.62K.
It is down -2.01% in the last 24 hours and down -11.86% over the past month.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
See More
Previous Close:
$3.49
Open:
$3.46
24h Volume:
187.62K
Relative Volume:
0.88
Market Cap:
$24.80M
Revenue:
-
Net Income/Loss:
$-29.96M
P/E Ratio:
-0.1238
EPS:
-27.6253
Net Cash Flow:
$-31.64M
1W Performance:
-2.56%
1M Performance:
-11.86%
6M Performance:
-66.76%
1Y Performance:
+11.40%
1-Day Range:
$3.3607
$3.55
1-Week Range:
$3.345
$3.97
52-Week Range:
$0.61
$14.68
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Name
Briacell Therapeutics Corp
Sector
Industry
Phone
(604) 921-1810
Address
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Compare BCTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCTX
Briacell Therapeutics Corp
|
3.42 | 25.30M | 0 | -29.96M | -31.64M | -27.63 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-22 | Initiated | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Stock (BCTX) Latest News
BriaCell (BCTX) Receives Positive Update from Data Safety Monitoring Board - GuruFocus
BriaCell (BCTX) Receives Positive Update from Data Safety Monito - GuruFocus
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast Cancer - Investing News Network
BriaCell Therapeutics Corp. (BCTX) Stock Price, News, Quote & History - Yahoo Finance
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer - lincolnjournal.com
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT at ASCO 2026 - Investing News Network
Breast cancer vaccine Bria-IMT shows 16.6-month survival, home-use potential - Stock Titan
BCTXL Price Today: BriaCell Therapeutics Corp. Warrant expiring 2031 Stock Price, Quote & Chart | MEXC - MEXC
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7 - Investing News Network
BriaCell develops ovarian cancer immunotherapy candidate - Investing.com India
Interfor Corporation - Baystreet.ca
BriaCell Therapeutics Developing Ovarian Cancer Immunotherapy Candidate - Moomoo
BriaCell develops ovarian cancer immunotherapy candidate By Investing.com - Investing.com Canada
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+ - Investing News Network
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™ - The Manila Times
Briacell expands pipeline to include an ovarian cancer immunotherapy candidate, Bria-Ova+(TM) - marketscreener.com
BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer - Sahm
TradingKey - TradingKey
BriaCell (BCTX) Completes Manufacturing for New Prostate Cancer Treatment - GuruFocus
BriaCell completes manufacturing of prostate cancer therapy - Investing.com
BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+ for Prostate Cancer - Investing News Network
BriaCell completes manufacturing of prostate cancer therapy By Investing.com - Investing.com South Africa
BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study - Sahm
BriaCell Therapeutics Corp. Revenue Breakdown – NASDAQ:BCTXZ - TradingView
BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study - Investing News Network
BriaCell (BCTX) Expands Clinical Trial Network for Advanced Brea - GuruFocus
Penn Medicine joins BriaCell phase 3 breast cancer trial By Investing.com - Investing.com Nigeria
Penn Medicine joins BriaCell phase 3 breast cancer trial - Investing.com
BriaCell enrolls 230+ patients in Phase 3 breast cancer trial, interim data expected in 2026 - Pluang
BriaCell enrolls over 230 patients in phase 3 breast cancer trial - Investing.com UK
BriaCell enrolls over 230 patients in phase 3 breast cancer trial By Investing.com - Investing.com South Africa
BriaCell Phase 3 Bria-IMT Study Enrollment Surpasses 230 Patients - Investing News Network
BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients - The Manila Times
MSN Money - MSN
BriaCell Therapeutics: Redefining Oncology with Personalized Cancer Immunotherapy - Investing News Network
Free float of BriaCell Therapeutics Corp. – NASDAQ:BCTXZ - TradingView
Briacell Therapeutics Corp Stock (BCTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):